Abiopharma

Canopy Growth Communication - Canopy Growth Congratulates Eric Ruhle on His Appointment to Vice President of Brand Sales at Canopy USA

ImmunoPrecise - ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

New Form 6-K - Haleon plc Filed: 2025-08-27 AccNo: 0001654954-25-010074 Size: 40 KB

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

New Form 8-K - Vor Biopharma Inc. Filed: 2025-08-27 AccNo: 0001193125-25-189169 Size: 386 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders Item 8.01: Other Events Item …

New Form 8-K - Quipt Home Medical Corp. Filed: 2025-08-27 AccNo: 0001558370-25-011770 Size: 167 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 6-K - Evaxion A/S Filed: 2025-08-27 AccNo: 0001171843-25-005608 Size: 14 KB

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

New Form 8-K - Trulieve Cannabis Corp. Filed: 2025-08-27 AccNo: 0001754195-25-000057 Size: 342 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - MANNKIND CORP Filed: 2025-08-27 AccNo: 0000950170-25-111586 Size: 239 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

New Form 8-K - Grace Therapeutics, Inc. Filed: 2025-08-27 AccNo: 0001140361-25-032847 Size: 193 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 6-K - GSK plc Filed: 2025-08-27 AccNo: 0001654954-25-010072 Size: 2 MB

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer